4//SEC Filing
Rosenberg Noah L. 4
Accession 0001209191-21-052083
CIK 0001438533other
Filed
Aug 16, 8:00 PM ET
Accepted
Aug 17, 7:39 PM ET
Size
7.5 KB
Accession
0001209191-21-052083
Insider Transaction Report
Form 4
Rosenberg Noah L.
Chief Medical Officer
Transactions
- Award
Common Stock
2021-08-13+4,500→ 49,021 total - Sale
Common Stock
2021-08-17$17.12/sh−1,407$24,085→ 47,614 total
Footnotes (2)
- [F1]On January 31, 2020, the reporting person was granted a performance restricted stock unit (PRSU) grant covering 9,000 shares of the Issuer's common stock, which vest upon the later of (i) 12 months from the date of grant and (ii) the achievement of specified clinical and regulatory development milestones. On August 13, 2021, a portion of the PRSUs vested upon the Issuer's confirmation of the satisfaction of a performance criterion related to the interim data read-out from the PROTECT study.
- [F2]Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested performance restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.
Documents
Issuer
Travere Therapeutics, Inc.
CIK 0001438533
Entity typeother
Related Parties
1- filerCIK 0001579649
Filing Metadata
- Form type
- 4
- Filed
- Aug 16, 8:00 PM ET
- Accepted
- Aug 17, 7:39 PM ET
- Size
- 7.5 KB